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Distribution of the a! and a2 chains of collagen IV and collagens V and
VI in Alport syndrome. We compared the distribution of the a! and a2
chains of collagen IV and of collagens V and VI in glomeruli of males
with Alport syndrome to their distribution in normal glomeruli and
glomeruli from patients with non-Alport renal diseases. aI(IV), a2(IV),
collagen V and collagen VI are normally restricted to the mesangium
and the subendothelial aspect of the glomerular basement membrane
(GBM). In contrast, these proteins were present throughout the entire
width of the GBM in Alport glomeruli. These alterations were apparent
in "early" Alport glomeruli, that is, those exhibiting minimal abnor-
malities by light microscopy, and they were further accentuated in
sclerosing Alport glomeruli. Obsolescent Alport glomeruli, in which the
capillary tuft had collapsed and few remaining cell nuclei were present,
exhibited nearly complete loss of al(IV) and a2(IV), like obsolescent
glomeruli in non-Alport diseased kidneys. However, the matrix of
obsolescent Alport glomeruli stained intensely for collagen V and
collagen VI, while these collagen types were not prominent in obsoles-
cent glomeruli of non-Alport diseased kidneys. These observations
suggest that the process of glomerulosclerosis in Alport kidneys has
attributes unique to this disease. It would also appear that mutations
affecting the Alport gene product have secondary effects on the
distribution of other GBM constituents.
Alport syndrome is a genetic renal disorder characterized by
a progressive glomerulopathy that is often associated with
sensorineural deafness and ocular lesions [1]. The disease is
usually transmitted as an X-linked dominant trait [2]. Recently,
mutations in an X-chromosomal gene, COL4A5, that encodes
the a5 chain of collagen IV were found in several kindreds with
Alport syndrome [3—8].
Males with Alport syndrome exhibit hematuria early in life,
and develop increasing proteinuria and impairment of glomer-
ular filtration with age [9]. Their glomerular basement mem-
branes (GBM) are initially thin but undergo progressive thick-
ening with time [10]. The homogeneous lamina densa of the
normal GBM is replaced by multiple, interlacing strands of
lamina densa-like material, which surround electron-dense bod-
ies of varying size [11—131. Alport GBM does not bind anti-
GBM autoantibodies from patients with Goodpasture syndrome
[14]. This abnormality appears to result from the absence of the
a3 and a4 chains of collagen IV from Alport GBM [15].
The mechanisms that drive the progressive GBM thickening
and renal functional deterioration typical of Alport syndrome
are unknown. Characterization of the composition of the extra-
cellular matrix of Alport glomeruli may provide some insight
into this question. In this report we describe ectopic distribu-
tion of the al and a2 chains of collagen IV, and of collagen V
and collagen VI, in Alport glomeruli.
Methods
Tissues
Kidney specimens were obtained from six unrelated males
aged 12 to 22 years in whom the diagnosis of Alport syndrome
was established on the basis of clinical and pathologic findings,
as previously described [16]. The transmission of the disease in
the family of each patient was consistent with inheritance of an
X-linked dominant mutation. In each case, monoclonal antibod-
ies directed against the a3(IV) and a4(IV) chains stained no
renal basement membranes, as previously described (Fig. 1)
[17]. The tissues represent the spectrum of the natural history of
the Alport renal lesion, from biopsies obtained early in the
course of the disease when glomerular filtration rate was
unimpaired, to nephrectomy specimens from dialysis-depen-
dent patients undergoing preparation for renal transplantation.
Figure 2 depicts the range of glomerular alterations observed
by light microscopy. We defined three "stages" of glomerular
alteration for the purposes of this study: early, in which
glomeruli exhibited normal cellularity and mildly increased
mesangial matrix; scierosing, in which hypercellularity, in-
creased mesangial matrix and/or hyalinosis, and periglomerular
fibrosis were apparent; and obsolescent, characterized by col-
lapsed capillary tufts with markedly decreased cellularity.
The non-Alport diseased kidneys studied were obtained from
patients with diabetic nephropathy (2 patients), dense intra-
membranous deposit disease (DIDD; membranoproliferative
glomerulonephritis, type 11—2 patients), idiopathic focal seg-
mental glomerulosclerosis (FSGS, 1 patient), obstructive urop-
athy (1 patient), and refiux nephropathy (1 patient). Normal
human kidney tissue consisted of uninvolved parenchyma in
nephrectomy specimens from a 41-year-old male with a fibrous
histiocytoma and a 29-year-old male with a germ cell tumor.
Antibodies
The rat monoclonal antibody 102 is directed against the NCI
domain of the al chain of collagen IV [18]. The sheep antibody
anti-M24 identifies the NC 1 domain of the a2 chain of collagen
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Fig. 1. lm,nunofluorescence of normal (A, C) and A/port glomeruli (B, D), stained with monoclonal antibodies against a3(IV) NCJ (A, B) and
a4(IV) NCJ (C, D). These antibodies bind to GBM of normal glomeruli but not to Alport GBM. (x 500)
IV [18]. These antibodies were provided by Dr. Ralph J.
Butkowski.
Goat anti-collagen V was purchased from Southern Biotech-
nology Associates (Binningham, Alabama, USA). The antibody
was raised against collagen V extracted from placenta, and
reacts with both human and bovine collagen V. According to
the manufacturer, the antibody was affinity-purified by cross-
absorption against collagens I, II, III, IV and VI and by specific
absorption to collagen V. Specificity for collagen V was con-
firmed by indirect ELISA, again by the manufacturer.
The mouse monoclonal antibody 5C6, which identifies colla-
gen VI [19], was obtained from the Developmental Studies
Hybridoma Bank at the University of Iowa. The Hybridoma
Bank is maintained by a contract from NICHD (NO1-HD-6-
2915). The antibody was provided to the Hybridoma Bank by
Dr. Eva Engvall.
Secondary antibodies consisted of fluorescein isothiocyanate
(FITC)-conjugated goat anti-rat IgG (Pel-Freeze, Rogers, Ar-
kansas, USA), FITC-conjugated rabbit anti-sheep IgG (Pci-
Freeze), and FITC-conjugated goat anti-mouse IgG (Caltag,
South San Francisco, California, USA). All secondary antibod-
ies were absorbed with normal human serum.
Immunohistologic methods
Immunofluorescence was performed using previously de-
scribed methods [161. Kidney tissues were snap-frozen in
isopentane pre-cooled in liquid nitrogen and stored at —70°C
until sectioning. Cryostat sections were made using a Lipshaw
cryostat maintained at constant temperature (25°C) and humid-
ity (30%), and fixed for 10 minutes in acetone (for nondenatured
sections) or ethanol (for denatured sections). Ethanol-fixed
sections were denatured by exposure to 0.1 M glycine, 6 M urea
(pH 3.5) for one hour at 4°C, as previously described [16]. This
procedure was necessary for optimal visualization of epitopes
reactive with the antibody against a2(IV) NC!.
Sections were incubated with primary antibodies followed by
FITC-conjugated secondary antibodies. Controls consisted of
sections incubated with secondary antibodies alone. All sec-
tions were incubated in ethidium bromide to demonstrate cell
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Fig. 2. Light microscopy of Alport glomeruli representing three stages of progression. (PAS, x 300) A. Early: There is segmental mesangial
hypercellularity, and the width of the mesangium is mildly increased. B. Scierosing: Cellularity is increased, with mesangial expansion, segmental
hyalinosis, and periglomerular fibrosis. C. Obsolescent: The glomerular capillary tuft is collapsed and wrinkled, and there are few remaining cell
nuclei.
nuclei, and p-phenylenediamene to retard fluorescence quench-
ing [201. The sections were examined using an epifluorescence
microscope with appropriate filters (Zeiss, Oberkochen, Ger-
many).
Results
al and a2 Chains of collagen IV
In glomeruli from normal kidneys al(IV) and a2(IV) were
confined to the mesangium and the subendothelial region of the
GBM (Fig. 3A, 4A and 5A). In Alport glomeruli showing
minimal histologic abnormalities ("early" Alport glomeruli)
al(IV) and a2(IV) were present throughout the width of the
GBM, as well as in the mesangium (Fig. 3B, 4B and SB). A
similar distribution of al(IV) and a2(IV) was observed in Alport
glomeruli showing more advanced histologic changes ("scieros-
ing" Alport glomeruli) as shown for al(IV) in Figure 3C. GBM
of obsolescent Alport glomeruli showed minimal staining for
al(IV) and a2(IV) (Fig. 3D).
As Kim et al have previously shown, al(IV) and a2(IV)
disappear from GBM during the course of diabetic nephropathy
[211 (Fig. 6A). Likewise, the GBM of DIDD kidneys shows no
staining for al(IV), although there is reactivity in the expanded
mesangium and in material within Bowman's space (Fig. 6B).
Obsolescent glomeruli in a kidney from a patient with idio-
pathic FSGS showed virtually no staining for al(IV) or a2(IV),
except within the thickened Bowman's capsule (Fig. 7B),
although intense GBM staining for a3(IV) was observed. Spec-
imens from patients with obstructive uropathy or reflux
nephropathy did not visibly differ from the FSGS kidney in
staining for al(IV) and a2(IV).
Collagen V
Glomeruli from normal kidneys exhibited staining for colla-
gen V in the mesangium and in the subendothelial region of the
GBM (Fig. 8A). Early Alport glomeruli also exhibited mesan-
gial collagen V. Rather than being restricted to the subendo-
thelial region of the GBM in these glomeruli, collagen V was
distributed throughout the width of the GBM (Fig. 8B). This
distribution pattern persisted in sclerosing Alport glomeruli
(Fig. 8C). Obsolescent Alport glomeruli stained intensely for
collagen V, with the reactivity concentrated in thick, ropy
collections of extracellular matrix (Fig. 8D).
The expanded mesangial regions of glomeruli from patients
with diabetic glomerulopathy or DIDD showed strong staining
for collagen V (Fig. 9A, 9C). However, GBM in these glomeruli
did not stain for collagen V. Obsolescent glomeruli in these
kidneys exhibited residual staining for collagen V in mesangial
regions, but no staining of GBM (Fig. 9B and D).
Obsolescent glomeruli in a kidney from a patient with idio-
pathic FSGS exhibited staining for collagen V which was
WI
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Fig. 3. Immunofluorescence of normal and A/port g/omeruli stained with monoclonal antibody (mAb) 102, which identifies al(IV) Nd. (X 500)
A. Normal: al(IV) is present in the mesangium and the subendothelial region of the glomerular basement membrane (GBM) and is also present
in Bowman's capsule, tubular basement membranes (TBM), and peritubular capillary basement membranes. B. Early Alport: al(IV) is present
throughout the width of the GBM. C. Selerosing Alport: Staining of diffusely expanded mesangium and the entire width of the thickened GBM is
present. Periglomerular and interstitial accumulation of al(IV) is also observed. U. Obsolescent Alport: Mesangial staining for al(IV) is virtually
absent. There is residual reactivity along the collapsed capillaries; by phase-contrast microscopy this reactivity appears to localize to the epithelial
aspect of the capillary wall. Substantial thickening of Bowman's capsule and TBM of atrophied tubules is observed, as in interstitial deposition
of al(IV).
concentrated in material within Bowman's space (Fig. 7C).
Staining within the glomerular tuft itself appeared to be re-
stricted to the mesangium. The staining pattern clearly differed
from that seen in obsolescent Alport glomeruli. Staining for
collagen V in kidneys from patients with obstructive uropathy
or reflux nephropathy did not differ significantly from the FSGS
kidney.
Collagen VI
Glomerular staining for collagen VI was restricted to mesan-
gium and subendothelial GBM in normal kidneys (Fig. bA). In
early Alport glomeruli, reactivity with anti-collagen VI anti-
body was present in mesangium and throughout the width of the
GBM (Fig. lOB). This staining pattern was preserved in scle-
rosing Alport glomeruli (Fig. bC). The pattern of collagen VI
staining in obsolescent Alport glomeruli resembled that seen for
collagen V, with staining concentrated in ropy collections of
extracellular matrix (Fig. 1OD).
In both diabetic and DIDD glomeruli the expanded mesangial
regions reacted strongly with the anti-collagen VI antibody
(Fig. 1 1A and C). However, GBM in these glomeruli showed no
staining for collagen VI. Residual staining for collagen VI was
present in mesangial regions of obsolescent glomeruli in dia-
betic and DIDD kidneys (Fig. 11B and D).
Obsolescent FSGS glomeruli showed residual collagen VI
staining within the mesangium as well as in material in Bow-
man's space, but GBM was not stained (Fig. 7D). Glomeruli in
kidneys of patients with obstructive uropathy or reflux
nephropathy resembled the FSGS kidney in collagen VI stain-
ing.
Discussion
The extracellular matrix of the glomeruli mesangium and
basement membrane (GBM) is composed of several collage-
nous constituents, including collagen types IV, V and VI. Five
distinct collagen IV a chains have been identified. The amino
acid and nucleotide sequences of al(IV) and a2(IV) have been
determined, and the genes encoding these chains mapped to
chromosome 13 [22—271. These chains are present in the gb-
merular mesangium and in the subendothelial region of the
GBM, in a completely concordant distribution [19, 28]. At this
time only partial amino acid sequences for the a3(IV) and
'U
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Fig. 4. Enlargements of panels A and B in Figure 3. The enhanced staining of Alport GBM (B) for al(IV) NC! is evident.
a4(IV) chains have been reported, and the bovine and human
a3(IV) genes have been partially sequenced [29—33]. In contrast
to al(IV) and a2(IV), these chains are absent from the mesan-
gium and are associated with the lamina densa region of the
GBM [19, 28, 34]. The gene encoding a fifth collagen IV a chain
has been cloned and mapped to the X chromosome [3—6].
Mutations in this gene have been found in affected members of
three kindreds with Alport syndrome [7, 8]. Although an
antibody generated against a synthetic a5(IV) peptide was
reported to stain GBM by indirect immunofluorescence, de-
tailed information on the distribution of this chain in extracel-
lular matrix has not yet been reported [3].
Studies in our laboratory using an anti-GBM alloantibody
from an Alport patient who developed anti-GBM nephritis after
renal transplantation and a monoclonal antibody have identified
a normal basement membrane epitope, absence of which has
proven to be a highly discriminating marker for Alport syn-
drome [16, 17, 35]. This "Alport antigen" has been mapped to
a 26 kD collagenase-resistant peptide representing the carboxy-
terminal globular domain of a basement membrane collagen a
chain [16, 36, 37]. Whether this a chain corresponds to the a5
chain of collagen IV, or is in fact a distinct chain, has not been
established. This molecule is also associated with the lamina
densa region of the GBM [17]. In general it is codistributed with
the a3(IV) and a4(IV) chains, except in certain basement
membranes, such as epidermal basement membrane, in which
the Alport antigen is present but the a3(IV) and a(IV) chains are
not [17].
Collagen V molecules are trimeric in composition, consisting
of al(V) and a2(V) chains in most tissues, while the placenta,
among other tissues, appears to include an a3(V) chain as well
[38—40]. In the kidney, collagen V has been localized to the
mesangium, GBM and renal interstitium [41, 42].
Collagen VI monomers are also composed of three chains,
the genes for which have been mapped to chromosomes 21 (al
and a2 chains) and chromosome 2 (a3 chain) [43]. The collagen
VI monomer consists of a large globular domain at each end
separated by a short triple helical region. These monomers
assemble into tetramers which associate in an end-to-end fash-
ion to form microfibrils [43]. Collagen VI has been demon-
strated in glomerular mesangium and GBM as well as in the
renal interstitium [20, 44].
The structural alterations that characterize glomerulosclero-
sis are accompanied by changes in the distribution of extracel-
lular matrix proteins within the glomerulus [45—49]. Studies of
sclerosing and obsolescent glomeruli in kidneys of patients with
diabetic nephropathy and membranous nephropathy have indi-
cated that the a3 and a4 chains of collagen IV persist in GBM
during glomerulosclerosis [18, 50]. Similarly, the "Alport anti-
gen," which has yet to be firmly identified, persists in the
collapsed GBM of obsolescent glomeruli. On the other hand,
120 Kashtan and Kim: Collagen IV, V and VI in Alport glorneruli
Fig. 5. Immunofluorescence of normal (A)
and Alport (B) glomeruli stained for ce2(IV)
NC]. Mesangium and subendothelial GBM in
the normal glomerulus are stained, while the
entire width of Alport GBM (arrows) is
stained. (x 460)
the al and a2 chains of collagen IV disappear from the GBM of persist as the glomerular tufts collapse into balls of matrix.
diseased glomeruli. Gubler et al found a normal distribution of collagen IV, or
Because of previous observations by ourselves and others nonspecific degenerative changes, in glomeruli of children with
that Alport GBM lacks a3(IV), a4(IV) and the Alport antigen Alport syndrome [52]. Thorner and colleagues described thick-
[17, 51, 52], we wondered how the biochemical aspects of ening of GBM staining for collagen IV in affected male dogs
glomerulosclerosis in Alport kidneys and non-Alport diseased with Samoyed hereditary nephropathy, a disease with histo-
kidneys might differ. The present study demonstrates unique pathologic and genetic similarities to Alport syndrome [53].
alterations in the localization of al(IV), a2(IV), collagen V and Alport syndrome is the only renal disorder in which we have
collagen VI in GBM of Alport glomeruli. These collagens, observed such changes in al(IV), a2(IV), collagen V and collagen
which are normally confined to the subendothelial region of VI. Since mesangial proliferation, mesangial matrix expansion and
GBM, are found throughout the width of Alport GBM. It would GBM thickening are characteristic histologic features of Alport
appear that with advancing sclerosis, al(IV) and a2(IV) disap- syndrome [54], we compared Alport glomeruli to glomeruli from
pear from Alport GBM. However, the diffusely thickened GBM patients with diabetic nephropathy or dense intramenibranous
of sclerosing and obsolescent Alport glomeruli appears to deposit disease (DIDD, membranoproliferative glomerulonephri-
progressively accumulate collagen V and collagen VI, which tis, type II), diseases in which mesangial expansion and GBM
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Fig. 6. Immunofluorescence of diabetic (A)
and dense intramembranous deposit disease
(B) glomeruli, stained with antibody against
cil(IV) Nd. Expanded mesangial regions of
these glomeruli stain positively for al(IV)
Nd, but GBMs (arrows) do not. Staining for
a2(IV) NC I was not distinguishable from
staining for al(IV) Nd. (X 460)
thickening also occur. Although the expanded mesangial regions
in diabetic and DIDD kidneys exhibited intense staining for
collagen V and collagen VI, the thickened GBMs in these kidneys
did not stain positively for these collagen types. We also compared
Alport glomeruli to glomeruli from patients with focal segmental
glomeruloscierosis of various etiologies, since the histological
lesion of focal segmental glomerulosclerosis is a characteristic
feature of the advanced Alport nephropathy [54]. While the Alport
GBM stained intensely for collagen V and collagen VI even in
advanced stages of sclerosis, histologically similar glomeruli from
patients with focal segmental glomerulosclerosis showed no GBM
staining for collagen V or collagen VI.
The primary event in the pathogenesis of the Alport glomer-
ulopathy is mutation in COL4A5, the gene encoding the aS
chain of collagen IV, as demonstrated by Barker et at [7}. The
mechanism(s) by which mutations in COL4A5 result in glomer-
ulosclerosis and renal failure have yet to be established. Mod-
ulation of gene transcription by extracellular matrix has been
demonstrated in vitro [55]. It is possible that changes in the
composition of Alport GBM initiated by defects in the a5(IV)
chain affect transcription of genes encoding matrix proteins,
leading to enhanced synthesis and deposition of al(IV), ci2(IV),
collagen V and collagen VI and perhaps other GBM constitu-
ents by glomerular endothelial cells and/or visceral epithelial
cells. GBM thickening and glomeruloscierosis in Alport kidneys
may reflect the accumulation of these products over time.
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FIg. 7. Jmmunofluorescence of obsolescent glomeruli in a nephrectomy specimen from a child with focal segmental glomerulosclerosis (X 500).
A. Anti-a3(IV) NC!: Note preservation of reactivity with collapsed, wrinkled GBM. B. Anti-a!(!V) NC!: There is minima! reactivity with the
glomerular tuft. There is intense staining of the thickened Bowman's capsule and tubular basement membranes. Antibody against the a2(IV) Nd
gave identical results. C. Anti-collagen V: There is persistent staining within the collapsed giomerular capillary tuft which appears to be localized
to the mesangium and to Bowman's space (arrow). D. Anti-collagen VI: There is persistent glomeru!ar staining which appears confined to the
mesangium.
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stained with anti-collagen V. Glomeruli in panels A and C exhibit mesangial expansion. Glomeruli in panels B and D are obsolescent (x 500), A
and C. Staining for collagen V in the expanded mesangium is apparent. The thickened GBMs (arrows) are not stained. B and D. There is residual
mesangial staining for collagen V, but no staining of GBM (arrows).
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Fig. 10. Immunofluorescence of normal and Alport glomeruli stained with mAb 5C6, which identifies collagen VI (X 500). A. Normal: Note the
predominantly mesangial localization of collagen VI. Collagen VI is also present in the subendothelial aspect of the GBM. B. Early Alport: Staining
of the expanded mesangium is apparent. GBM reactivity is increased in both intensity and width. C. Sclerosing Alport: This glomerulus exhibits
diffuse although inhomogeneous enhancement of staining for collagen VI in GBM, as well as in the expanded mesangium. Penglomerular
deposition of collagen VI can also be discerned. D. Obsolescent Alport: Thickened, collapsed capillary loops exhibit intense staining for collagen
VI.
related Alport males with Alport syndrome. J Lab Clin Med
116:508—515, 1990
38. BURGESON RE, EL-ALDI FA, KAITILO II, HOLLISTER DW: Fetal
membrane collagens: Identification of two new collagen alpha
chains. Proc NatI Acad Sci USA 73:2579—2583, 1976
39. CHUNG E, RHoDEs RK, MILLER EJ: Isolation of three collagenous
components of probable basement membrane origin from several
tissues. Biochem Biophys Res Commun 71:1167—1174, 1976
40. FESSLER JH, SHIGAKI N, FESSLER LI: Biosynthesis and properties
of procollagen V. Ann NYAcad Sci 460:181—186, 1985
41. ROLL FJ, MADRI JA, ALBERT JA, FURTHMAYR H: Codistribution
of collagen types IV and AB2 in basement membranes and mesan-
gium of the kidney. J Cell Biol 85:597—616, 1980
42. MARTINEZ-HERNANDEZ A, GAY S, MILLER EJ: Ultrastructural
localization of type V collagen in rat kidney. J CeIlBiol 92:343—349,
1982
43. CHU M-L, PAN T-C, CONWAY D, SAI-I-FA B, STOKES D, Kuo H-J,
GLANVILLE RW, TIMPL R, MANN K, DEUTZMANN R: The struc-
ture of type VI collagen. Ann NYAcad Sci 580:55—63, 1990
44. VON DER MARK H, AUMAILLEY M, WIcK G, FLEISCHMAJER R,
TIMPL R: Immunochemistry, genuine size and tissue localization of
collagen VI. Eur J Biochem 142:493—502, 1984
45. STRIKER LM, KILLEN PD, Cm E, STRIKER GE: The composition of
glomeruloscierosis: I. Studies in focal sclerosis, crescentic glomer-
ulnephritis, and membranoproliferative glomerulonephritis. Lab
Invest 51:181—192, 1984
46. YOSHIOKA K, TAKEMURA T, MATSUBARA K, MIYAMOTO H,
AKANO N, MAKI S: Immunohistochemical studies of refiux
nephropathy: The role of extracellular matrix, membrane attack
complex, and immune cells in glomerular sclerosis. Am J Pathol
129:223—231, 1987
47. YOSHIOKA K, TAKEMURA T, TOHDA M, AKANO N, MIYAM0T0 H,
O0sHIMA A, MAKI 5: Glomerular localization of type III collagen in
human kidney disease. Kidney mt 35:1203—1211, 1989
48. OoMuI A, NAKEMURA T, ARAKAWA M, O0SHIMA A, IsEMui
M: Alterations in the extracellular matrix components in human
glomerular diseases. Virchows Archiv A Pathol Anat 415:151—159,
1989
49. FUNABIKI K, HORIKOSHI 5, ToMINo Y, NAGAI Y, KOIDE H:
Immunohistochemical analysis of extracellular components in the
glomerular sclerosis of patients with glomerulonephritis. Clin
Nephrol 34:239—246, 1990
50. KIM Y, BuTKowsKI R, BURKE B, KLEPPEL MM, CROSSON J, KATZ
A, MICHAEL AF: Differential expression of basement membrane
collagen in membranous nephropathy. Am J Pathol (in press)
51. SAVAGE COS, PUSEY CD, KERSHAW MJ, CASHMAN SJ, HARRISON
P, HARTLEY B, TURNERDR, CAMERON JS, EVANS DJ, LOCKWOOD
CM: The Goodpasture antigen in Alport's syndrome: Studies with
a monoclonal antibody. Kidney mt 30:107—112, 1986
52. GUBLER MC, MOUNIER F, GROS F, WIESLANDER J, BEZAIU A,
GUICHARNAUD L: Glomerular distribution of subunits Ml and M2
of the globular domain of basement membrane collagen in Alport's
syndrome, in Progress in Basement Membrane Research: Renal
and Related Aspects in Health and Disease, edited by GUBLER
T '1
.—. 4
"I
4
T?t SL,d
S.
. t
'II..
1±
.
126 Kashtan and Kim: Collagen IV, V and VI in Alport glomeruli
Fig. 11. Immunofluorescence of glomeruli from patients with diabetic nephropathy (A and B) or dense intramembranous deposit disease (C and
D), stained for collagen VI. Glomeruli in panels A and C exhibit mesangial expansion. Glomeruli in panels B and D are obsolescent (x 500). A and
C. Expanded mesangial areas exhibit intense staining for collagen VI. The thickened GBMs show no reactivity (arrows). B and D. Obsolescent
glomeruli show some residual staining for collagen VI. Compare with Figure 3D.
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